Praxis Precision Medicines to Participate in Upcoming Investor Conferences

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation inhibition imbalance, announced it will be attending and presenting at the following upcoming investor events: 

• Truist Securities BioPharma Symposium: a corporate presentation will take place on Thursday, November 6, 2025, at 10:40am ET at the Lotte New York Palace Hotel in New York City.
  
• HC Wainwright Emerging Ideas on BioPharma: Fireside Chat with H.C. Wainwright analyst Doug Tsao, Friday, November 7, 2025 at 12:30pm ET. Registration link available here.
• Guggenheim Securities Inaugural Healthcare Innovation Conference: a corporate presentation will take place on Monday, November 10, 2025, at 9:30am ET at the InterContinental Boston in Boston, MA. A live webcast of the presentation will be available here.
  
• Jefferies Global Healthcare Conference: a corporate presentation will take place on Tuesday, November 18, 2025, at 1:30pm GMT at the Waldorf Hilton in London, UK. A live webcast of the presentation will be available here.
  
  

Replays of the third quarter earnings webinar and the conference webcasts will be available on Praxis’ “Events and Presentations” website after each event for approximately 90 days.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.

Investor Contact:
Praxis Precision Medicines
[email protected]
857-702-9452

Media Contact:
Dan Ferry
Life Science Advisors
[email protected]
617-430-7576

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)